



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/48	A1	(11) International Publication Number: WO 96/36320 (43) International Publication Date: 21 November 1996 (21.11.96)
(21) International Application Number: PCT/US96/06844 (22) International Filing Date: 14 May 1996 (14.05.96) (30) Priority Data: 08/446,891 17 May 1995 (17.05.95) US (71) Applicant: R.P. SCHERER CORPORATION [US/US]; 2075 West Big Beaver Road, Troy, MI 48007-7060 (US). (72) Inventor: TANNER, Keith; 1403 Crestwood Court, Safety Harbor, FL 34695 (US). (74) Agent: DREHKOFF, W., Dennis; Banner & Allegretti, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AU, BR, CA, JP, KR, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: FILL COMPOSITIONS FOR SOFT ELASTIC GEL CAPSULES (57) Abstract <p>A dosage unit form comprises a biologically active agent, such as a pharmaceutical, nutritional supplement or diagnostic, dissolved or suspended in a carrier liquid encapsulated in a soft elastic gel capsule. The carrier liquid comprises maltitol syrup as a major component. Maltitol syrup may be the only component of the carrier liquid, or may be blended with other liquids and/or excipients.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CZ	Czechoslovakia	LU	Luxembourg	TD	Chad
CS	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

SPECIFICATION**FILL COMPOSITIONS FOR SOFT ELASTIC GEL CAPSULES**BACKGROUND OF THE INVENTIONField of the Invention and
Description of the Prior Art

5 This invention is concerned with improvements in and relating to pharmaceutical compositions, nutritional supplements, and diagnostics. More particularly, it is concerned with such compositions in dosage unit form encapsulated in soft elastic gelatin (SEG) capsules.

10 Pharmaceutical compositions in dosage unit form encapsulated in SEG capsules are well known and generally consist of a fill material comprising one or more active agents dissolved or suspended in an appropriate liquid or paste vehicle, encapsulated in a soft gelatin shell, typically comprising gelatin together with a plasticizer. Manufacture of SEG capsules requires the fill material to be a pumpable liquid or paste. The carrier liquid can be a single or a multi-component system that
15 must be compatible with the SEG capsule.

- 2 -

Liquids used in SEG capsules fall into two general categories, hydrophilic and lipophilic. There are many examples of acceptable lipophilic liquids used in the SEG format. Usually these are oils and are not water soluble. Due to the poor solubility of lipophilic liquids in water and gastric medium, they tend to have poor dispersion properties in the stomach, however. For this reason, formulations of pharmaceutical active ingredients and lipophilic carriers can retard the release of these active ingredients into the gastric fluid. It is often advantageous to prepare the active ingredients in solution for reasons of improved bioavailability and faster onset of action. Unfortunately, lipophilic liquids are poor solvents for many pharmaceutical active ingredients. These disadvantages can be overcome by using hydrophilic liquids.

There are few hydrophilic liquids suitable for use as carrier liquids in this application. The most versatile of these carriers in general use is polyethylene glycol, particularly in the molecular weight range of 200-800. This material offers good dispersion in gastric medium, excellent solubilizing capabilities for pharmaceutical active ingredients and good compatibility in the SEG format. However, there are disadvantages to using this material. One major disadvantage is that of instability; polyethylene glycol while in the presence of atmospheric oxygen reacts to form aldehydes. The residual aldehyde content of polyethylene glycol will react with the gelatin shell causing the protein polymers to inter- and intra-crosslink. The net result is a crosslinked gelatin shell that is insoluble in gastric media. To

- 3 -

reduce this problem, polyethylene glycol must be handled in an inert atmosphere, for example, under a nitrogen blanket. Polyethylene glycol is also implicated as a potential irritant to mucous membranes found in the gastrointestinal tract.

Another class of hydrophilic liquids is non-ionic surfactants. These also have the disadvantage of being potential mucous membrane and stomach irritants. Common examples of materials in this category are polysorbate 80 and polysorbate 20. Legislation permits only small quantities of these materials to be ingested daily in over-the-counter and nutritional supplement products. This can restrict the use of these materials as a major component of a carrier system. A further disadvantage of non-ionic surfactants is that their inherent surface activity can have an adverse effect on the formation of the capsule seals, leading to a leaking product.

Sugar solutions are another category of hydrophilic carrier liquids. However, concentrated sugar solutions, such as glucose syrup, sorbitol solution and maltose syrup, are not particularly suitable for this application due to their adverse effect on gelatin capsules. Sorbitol causes excessive plasticization of the gelatin wall leading to deterioration of the capsule. Concentrated sugar solutions containing reducing sugars are also incompatible with gelatin. The reason is that the reactive aldehyde isomers of reducing sugars will cause gelatin crosslinking and unacceptable Maillard browning reactions. Common reducing sugars are dextrose and fructose which are present in glucose and maltose syrups. Also, concentrated aqueous solutions of sucrose are not sufficiently hygroscopic to retain water within an SEG capsule leading

- 4 -

to distorted capsule shapes and crystalline sugar in the fill. Concentrated sugar solutions do have the advantage over previous examples of not being mucous membrane irritants, but some examples can cause some gastric disturbances due to their potential laxative properties when ingested in large amounts. This is particularly true of sorbitol.

U.S. Patent No. 4,935,243 is directed to chewable, edible soft gelatin capsules with a shell of water, gelatin, plasticizer and hydrogenated starch hydrolysate, added to render the shell dispersible and soluble in the mouth. The SEG capsule contains a fill material with an active ingredient dispersed or dissolved in it. The hydrogenated starch hydrolysate in the capsule shell, which is used to augment the taste and chewability of the shell, is said to include hydrolysates "which contain less than 3% of polyols whose degree of polymerization (DP) is higher than 20, about 35-60% of maltitol (DP 2), about 0.1-20% of sorbitol (DP 1), and the balance being constituted by a mixture of polyols of DP 3-20."

U.S. Patent No. 4,465,667 describes suspensions of aluminum hydroxide based antacid components in suspension form, stabilized with a hydrogenated hydrolysed glucose polymer in an amount of 2-30% by weight. Stabilizing agents disclosed include "a sugar alcohol [sic] as xylitol, mannitol, sorbitol or glycerol, by mixture of sugar alcohols obtained at the preparation of xylitol or a sugar such as glucose, maltose, fructose, or saccharose." Examples of specific stabilizing agents for the antacid suspension include LYCASIN[®], the trademark for a syrup prepared

- 5 -

by catalytic hydrogenation or reduction of a high maltose syrup obtained by the enzymatic hydrolysis of food starch. LYCASIN[®] is available from Roquette Corporation, Gurnee, Illinois.

U.S. Patent No. 2,580,683, issued January 1, 1952, is directed to "a stable
5 gelatin capsule inclosing an aqueous solution having hygroscopic material present in a quantity of a magnitude preventing deterioration of the capsule by the aqueous constituent of the solution."

SUMMARY OF THE INVENTION

10 Applicant has devised an alternative carrier liquid for active ingredients in SEG capsules which provides significant advantages as compared with the prior art carrier liquids described above. The invention utilizes maltitol [4-O- α -D-glucopyranosyl-D-glucitol] syrup to either dissolve or suspend pharmaceutical actives, nutritional supplements or diagnostics, which can then be encapsulated into soft gel
15 capsules during the rotary die manufacturing process. Maltitol syrup can be the only component of the carrier medium or may be blended with other commonly used encapsulatable liquids and/or excipients. A sizable component should always be maltitol syrup.

Objects and advantages of the present invention include the following:

20

- 6 -

The invention provides good chemical stability for the capsule fill material.

Unlike many non-hydrogenated concentrated sugar solutions, maltitol syrup is chemically very stable and therefore more compatible with drug systems.

As the carrier liquid for the active ingredient within SEG capsules, maltitol provides the advantage of compatibility with the SEG format. Maltitol syrup is hydrogenated glucose syrup and is compatible with SEG capsules. The hydrogenation process stabilizes the system; no reducing sugars are present. It is chemically more inert and is resistant to oxidation from atmospheric oxygen. Due to its chemical inertness, it will not cause gelatin crosslinking. Unlike many sugar solutions, Maltitol syrup is not prone to recrystallization of sugar components even at high concentrations.

Maltitol syrup offers favorable drug solubilities.

Maltitol syrup offers superior biocompatibility over many alternative fill materials in SEG capsules. The syrup does have some laxative properties, but is significantly less laxative than sorbitol syrup. Due to the low irritancy towards mucous membranes, it is ideally suited for suppository and vaginal applications where high doses of the carrier liquid are in intimate contact with sensitive tissues. Capsules designed for ingestion use can be either swallowable or chewable.

Maltitol syrup has a pleasant sweet taste and is often used commercially as a bulk sweetener. The sweetening power is similar to that of sucrose. This property can be used to prepare suspensions or solutions of actives that when combined with

- 7 -

suitable flavors and excipients will produce palatable mixtures. Fill materials prepared in such a manner are ideally suited to chewable applications. Due to the sweet nature of maltitol syrup it helps to mask the flavor of certain unpalatable drugs. The dosage formats of the present invention can be ingestible, chewable, buccal, suppository, or vaginal types. The applications are in the field of human medicinal/nutritional supplements and diagnostics and veterinary applications.

Thus, maltitol syrup is a hydrophilic liquid suitable for use as a carrier liquid in SEG capsules which is both safe to use and compatible with the gelatin shell of the capsules. The invention contemplates a dosage unit form comprising a biologically active agent dissolved or suspended in a carrier liquid encapsulated in a soft elastic gelatin capsule, wherein the carrier liquid comprises at least about 20% maltitol syrup.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention provides SEG unit dosage forms that utilize the novel carrier medium, maltitol syrup. Maltitol syrup is a medium viscosity liquid, manufactured by hydrogenation of glucose syrup to produce sugar alcohols. It has been available commercially since the late 1950's. Inclusion of water in maltitol syrup is required to produce a mobile liquid and water is present in the syrup as commercially supplied.

- 8 -

Maltitol syrup can be formulated with many drugs and biological actives and diagnostic agents for use as a solution or a pumpable suspension. Pharmaceutical active ingredients may include, e.g., monograph drugs and proprietary drugs. Nutritional supplements in the maltitol carrier may include vitamins, active metabolites, minerals, and plant extracts, as well as other nutritional additives or agents. Diagnostic agents include radiolabelled biochemicals and other diagnostic tools. Biologically active agents suitable for use with the present invention include, without limitation, those selected from the group consisting of antihistamine formulations, analgesic formulations including non-steroidal anti-inflammatory drugs (NSAID'S), antibiotics/antibacterials, antacid formulations, breath freshener formulations, allergy/sinus formulations, expectorants, sedatives, sore throat soothers, local anesthetics, laxative formulations, steroids, bronchodilators, prophylactic dental products such as fluoride or dentifrices, cough suppressants, vitamins, herbal extracts, motion sickness preventatives, antifungal formulations, anti-yeast formulations and diet aids. Maltitol syrup may also serve as a carrier for cosmetic and confectionery products.

The novel maltitol syrup carrier system may be used instead of or combined with other conventional liquids for one or more of the following reasons: 1) improved stability, 2) solubility, 3) greater biocompatibility, 4) improved dissolution, 5) legislative constraints, 6) novelty and 7) palatability. The major component (about 20% or greater) of the carrier liquid would always be maltitol syrup. Preferably, the

- 9 -

maltitol has a solids loading of approximately 75% or 85%. Suspensions of active ingredients in maltitol syrup may benefit by containing rheological modifiers to prevent sedimentation. As noted above, the carrier system of the present invention comprises at least about 20% maltitol syrup. However, the benefits of the invention are particularly evident when the carrier system comprises at least about 50% maltitol syrup.

The inventive dosage forms may be used to administer biologically active agents both for human and animal consumption. For example, the novel liquid carrier system of the invention may be used in SEG capsules to provide prescription pharmaceuticals, over the counter drugs, nutritional supplements or diagnostics introduced orally, buccally, rectally, or by vaginal insertion in both human and veterinary applications.

Preparations of either solutions or suspensions of actives in maltitol syrup are prepared by the following methods:

1. Solutions

Maltitol syrup is dispensed into a suitable mixing vessel. Actives and solubilizing agents are added in sequence to the liquid and homogenized with high shear blending. If required, heat can be applied to the system to facilitate dissolution; normally temperatures in excess of 60 degrees centigrade are not required. The mixture once clear and free of particular matter is cooled and

- 10 -

deaerated. During deaeration care must be taken to ensure that water loss is minimized; otherwise there may be an adverse effect on drug solubility.

Encapsulation of the liquid is performed on a standard rotary die encapsulation machine. Capsules are dried in low humidity conditions. Care must be taken not to
5 over dry the capsules, as this could lead to deformed capsules due to excessive loss of water from the fill.

2. Suspensions

Maltitol syrup is dispensed into a suitable mixing vessel. Actives are added to the liquid and the mixture homogenized using high shear mixing techniques.
10 Suspending agents if required are added to the system and depending on the nature of the material homogenized using the appropriate degree of shear. The mixture is deaerated; care is taken during this process to minimize any water loss. Capsules are manufactured using the rotary die encapsulation machine. Excessive drying of the capsules must be avoided. Capsule size will be determined by the required potency
15 of the active ingredient, the application and product aesthetics.

Examples of both solution and suspension fill formulations in maltitol syrup are provided below:

EXAMPLE 1 Allergy Formulation

<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
Maltitol Syrup 75 %	719.0
Pseudoephedrine Hydrochloride	30.0

- 11 -

<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
Brompheniramine Maleate	1.0
Capsule Fill Weight	750.0

EXAMPLE 2

Antihistamine Formulation

<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
Maltitol Syrup 85%	210.0
Diphenylhydramine Hydrochloride	50.0
Capsule Fill Weight	260.0

EXAMPLE 3

Antacid Formulation

<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
Maltitol Syrup 75%	434.0
Calcium Carbonate	540.0
Simethicone	20.0
Polysorbate 80	6.0
Capsule Fill Weight	1000.0

EXAMPLE 4

Chewable Antacid Formulation

<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
Maltitol Syrup 75%	1401.0
Calcium Carbonate	1030.0
Peppermint Oil	4.0
Sodium Crosscarmellose gum	20.0
Capsule Fill Weight	2455.0

- 12 -

EXAMPLE 5
Analgesic Formulation

5	<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
	Lycasin 75%	700.0
	Acetaminophen	500.0
	Capsule Fill Weight	1200.0

EXAMPLE 6
Analgesic Formulation

15	<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
	Ibuprofen	200.0
	Lycasin 75%	800.0
	Capsule Fill Weight	1000.0

EXAMPLE 7
Chewable Breath Freshener Formulation

25	<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
	Lycasin 75%	584.0
	Peppermint Oil	3.0
	Polysorbate 80	3.0
30	Capsule Fill Weight	590.0

EXAMPLE 8
Laxative Formulation

35	<u>COMPONENT</u>	<u>MG/SOFTGEL</u>
	Lycasin 75%	966.7
	Senna Extract 60% A+B	33.3
40	Capsule Fill Weight	1000.0

- 13 -

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit or scope of the invention as set forth in the appended claims.

- 14 -

I CLAIM:

1. A dosage unit form comprising a biologically active agent dissolved or suspended in a carrier liquid encapsulated in a soft elastic gel capsule, wherein the carrier liquid comprises at least about 20% maltitol syrup.

5

2. The dosage unit form of claim 1 wherein the carrier liquid also contains at least one encapsulatable carrier liquid or excipient in addition to maltitol syrup.

10

3. The dosage unit form of claim 1 wherein the biologically active agent is selected from the group consisting of pharmaceuticals, nutritional supplements and diagnostics, cosmetics and confectionery products.

15

4. The dosage unit form of claim 1 wherein the biologically active agent is a pharmaceutical.

5. The dosage unit form of claim 1 wherein the biologically active agent is a nutritional supplement.

20

6. The dosage unit form of claim 1 wherein the carrier liquid combined with the biologically active agent comprise a solution.

- 15 -

7. The dosage unit form of claim 1 wherein the carrier liquid combined with the biologically active agent comprise a pumpable suspension.

8. The dosage unit form of claim 1 wherein the carrier liquid also
5 contains a rheological modifier.

9. The dosage unit form of claim 1 wherein the capsule is designed to be introduced by a mode selected from the group consisting of oral, buccal, rectal and vaginal insertion.

10. The dosage unit form of claim 1 wherein the biologically active agent is selected from the group consisting of analgesic formations, antihistamine formulations, antibiotics, antacid formulations, breath freshener formulations, allergy/sinus formulations, expectorants, sedatives, sore throat soothers, local
15 anesthetics, laxative formulations, steroids, bronchodilators, prophylactic dental products, cough suppressants, vitamins, herbal extracts, motion sickness preventatives, antifungal formulations, anti-yeast formulations and diet aids.

11. The dosage unit form of claim 1 wherein the carrier liquid is a syrup
20 obtained by catalytic hydrogenation or reduction of a high maltose syrup obtained from the enzymatic hydrolysis of food starch.

- 16 -

12. The dosage unit form of claim 1 wherein the carrier liquid comprises at least about 50% maltitol syrup.

13. The dosage unit form of claim 1 wherein the maltitol syrup has a solids loading of approximately 75%.

14. The dosage unit form of claim 1 wherein the maltitol syrup has a solids loading of approximately 85%.

15. The dosage unit form of claim 1 wherein the gel capsule is chewable.

INTERNATIONAL SEARCH REPORT

Int. Appl. No.
PCT/US 96/06844

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

Y PATENT ABSTRACTS OF JAPAN
vol. 15, no. 112 (C-0815), 18 March 1993
& JP.A,30 005418 (KOWA CO), 11 January
1991,
see abstract

Y AM. J. HOSP. PHARM,
vol. 50, no. 4, 1993, USA,
pages 693-698, XP000575095
K.S. ALEXANDER ET AL: "STABILITY OF
PROCAINAMIDE HYDROCHLORIDE SYRUPS
COMPOUNDED FROM CAPSULES"
see page 694, left-hand column, line 13-35
see abstract

-/--

1-15

1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

'A' document defining the general state of the art which is not
considered to be of particular relevance
'E' earlier document but published on or after the international
filing date
'L' document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)
'O' document referring to an oral disclosure, use, exhibition or
other means
'P' document published prior to the international filing date but
later than the priority date claimed

'T' later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

'X' document of particular relevance; the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step when the document is taken alone
'Y' document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

'Z' document member of the same patent family

Date of the actual completion of the international search

19 August 1996

Date of mailing of the international search report

29.08.96

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/US 96/06844

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE WPI Week 9616 Derwent Publications Ltd., London, GB; AN 96-154781 XP002010982 & JP,A,08 038 093 (TAKASAGO INT CORP USA) , 13 February 1996 see abstract</p> <p>---</p>	1-15
Y	<p>US,A,4 465 667 (BYROED EVA K ET AL) 14 August 1984 cited in the application see the whole document</p> <p>---</p>	1-15
Y	<p>US,A,2 580 683 (PIETER KRUEGER, BUSUM NETHERLANDS) 1 January 1952 cited in the application see the whole document</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 96/06844

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4465667	14-08-84	AR-A- 228854	29-04-83
		AT-T- 1968	15-12-82
		AU-B- 535403	22-03-84
		AU-B- 5973480	15-01-81
		CA-A- 1146860	24-05-83
		EP-A- 0022429	14-01-81
		JP-B- 1011008	23-02-89
		JP-C- 1527602	30-10-89
		JP-A- 56018922	23-02-81
		SE-A- 7905972	10-01-81

US-A-2580683	01-01-52	FR-A- 959520 NL-C- 63297	31-03-50
